Syndax Pharmaceuticals Inc SNDX
$19.65 $0.10 (0.51%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
SNDX Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Syndax Pharmaceuticals Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Syndax Pharmaceuticals Inc. Stock Analysis SNDX
United States Health Care Small Cap Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 298 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. The company is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. The company is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Syndax Pharmaceuticals Inc (SNDX) Chart
Financial Metrics & Statements of Syndax Pharmaceuticals Inc (SNDX)
FAQ's for Syndax Pharmaceuticals Inc (SNDX)
- As of August 2026, Syndax Pharmaceuticals Inc SNDX is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Syndax Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Syndax Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Syndax Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Syndax Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Syndax Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Syndax Pharmaceuticals Inc (SNDX)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
